JP2018519251A5

JP2018519251A5 -

Download PDF

Info

Publication number: JP2018519251A5
Authority: JP; Japan
Prior art keywords: individual; smoking; composition; nicotine; treatment
Prior art date: 2016-04-26
Legal status : Granted

Application number

JP2017555768A

Other languages

English (en)

Japanese (ja)

Other versions

JP6675688B2 (ja

JP2018519251A (ja

Filing date

2016-04-26

Publication date

2019-05-30

2016-04-26 Application filed filed Critical

2016-04-26 Priority claimed from PCT/US2016/029308 external-priority patent/WO2016176177A1/en

2018-07-19 Publication of JP2018519251A publication Critical patent/JP2018519251A/ja

2019-05-30 Publication of JP2018519251A5 publication Critical patent/JP2018519251A5/ja

2020-04-01 Application granted granted Critical

2020-04-01 Publication of JP6675688B2 publication Critical patent/JP6675688B2/ja

Status Active legal-status Critical Current

2036-04-26 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 claims description 586
238000011282 treatment Methods 0.000 claims description 274
238000000034 method Methods 0.000 claims description 239
239000003814 drug Substances 0.000 claims description 203
230000000391 smoking effect Effects 0.000 claims description 154
150000003839 salts Chemical class 0.000 claims description 153
229940079593 drug Drugs 0.000 claims description 140
239000012453 solvate Substances 0.000 claims description 140
230000004584 weight gain Effects 0.000 claims description 126
235000019786 weight gain Nutrition 0.000 claims description 126
239000000203 mixture Substances 0.000 claims description 119
150000004677 hydrates Chemical class 0.000 claims description 111
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 104
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 103
229960002715 nicotine Drugs 0.000 claims description 100
208000025569 Tobacco Use disease Diseases 0.000 claims description 99
206010057852 Nicotine dependence Diseases 0.000 claims description 93
241000208125 Nicotiana Species 0.000 claims description 85
235000002637 Nicotiana tabacum Nutrition 0.000 claims description 84
230000005586 smoking cessation Effects 0.000 claims description 80
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 78
208000008589 Obesity Diseases 0.000 claims description 69
235000020824 obesity Nutrition 0.000 claims description 68
230000037221 weight management Effects 0.000 claims description 59
238000004519 manufacturing process Methods 0.000 claims description 58
235000019505 tobacco product Nutrition 0.000 claims description 54
206010012335 Dependence Diseases 0.000 claims description 45
239000008194 pharmaceutical composition Substances 0.000 claims description 45
230000002265 prevention Effects 0.000 claims description 34
230000002829 reductive effect Effects 0.000 claims description 29
235000019504 cigarettes Nutrition 0.000 claims description 23
230000037406 food intake Effects 0.000 claims description 22
235000012631 food intake Nutrition 0.000 claims description 22
206010015037 epilepsy Diseases 0.000 claims description 20
239000012752 auxiliary agent Substances 0.000 claims description 18
230000001939 inductive effect Effects 0.000 claims description 17
230000036186 satiety Effects 0.000 claims description 17
235000019627 satiety Nutrition 0.000 claims description 17
208000007848 Alcoholism Diseases 0.000 claims description 16
208000011117 substance-related disease Diseases 0.000 claims description 16
208000011580 syndromic disease Diseases 0.000 claims description 16
206010013663 drug dependence Diseases 0.000 claims description 11
241001465754 Metazoa Species 0.000 claims description 10
238000012544 monitoring process Methods 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 9
206010046543 Urinary incontinence Diseases 0.000 claims description 8
238000002560 therapeutic procedure Methods 0.000 claims description 5
230000008569 process Effects 0.000 claims description 3
125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims 1
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 190
208000021017 Weight Gain Diseases 0.000 description 108
230000009467 reduction Effects 0.000 description 84
208000016261 weight loss Diseases 0.000 description 81
230000004580 weight loss Effects 0.000 description 81
-1 gums Substances 0.000 description 75
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 67
102000005962 receptors Human genes 0.000 description 58
108020003175 receptors Proteins 0.000 description 58
239000003795 chemical substances by application Substances 0.000 description 38
210000000577 adipose tissue Anatomy 0.000 description 35
201000010099 disease Diseases 0.000 description 35
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
239000002552 dosage form Substances 0.000 description 34
208000035475 disorder Diseases 0.000 description 32
230000000694 effects Effects 0.000 description 31
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 29
206010033307 Overweight Diseases 0.000 description 26
239000004480 active ingredient Substances 0.000 description 26
239000000018 receptor agonist Substances 0.000 description 25
229940044601 receptor agonist Drugs 0.000 description 25
208000024891 symptom Diseases 0.000 description 25
206010020772 Hypertension Diseases 0.000 description 24
239000000047 product Substances 0.000 description 24
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 23
230000006399 behavior Effects 0.000 description 23
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 23
230000007423 decrease Effects 0.000 description 23
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 22
239000008103 glucose Substances 0.000 description 22
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 21
208000032928 Dyslipidaemia Diseases 0.000 description 21
208000017170 Lipid metabolism disease Diseases 0.000 description 21
230000001276 controlling effect Effects 0.000 description 20
230000001965 increasing effect Effects 0.000 description 20
238000009472 formulation Methods 0.000 description 19
238000002360 preparation method Methods 0.000 description 19
206010010904 Convulsion Diseases 0.000 description 18
WRZCAWKMTLRWPR-VSODYHHCSA-N lorcaserin hydrochloride hemihydrate Chemical compound O.Cl.Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12.C[C@H]1CNCCC2=CC=C(Cl)C=C12 WRZCAWKMTLRWPR-VSODYHHCSA-N 0.000 description 18
239000008280 blood Substances 0.000 description 17
210000004369 blood Anatomy 0.000 description 17
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 17
DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 17
239000000902 placebo Substances 0.000 description 17
229940068196 placebo Drugs 0.000 description 17
239000000843 powder Substances 0.000 description 17
229940025084 amphetamine Drugs 0.000 description 16
239000000883 anti-obesity agent Substances 0.000 description 16
229940120049 belviq Drugs 0.000 description 16
239000003826 tablet Substances 0.000 description 16
230000007812 deficiency Effects 0.000 description 15
206010012601 diabetes mellitus Diseases 0.000 description 15
229960003638 dopamine Drugs 0.000 description 15
239000007788 liquid Substances 0.000 description 15
239000000243 solution Substances 0.000 description 15
208000024827 Alzheimer disease Diseases 0.000 description 14
239000000556 agonist Substances 0.000 description 14
230000006872 improvement Effects 0.000 description 14
238000002670 nicotine replacement therapy Methods 0.000 description 14
208000020016 psychiatric disease Diseases 0.000 description 14
229940076279 serotonin Drugs 0.000 description 14
239000007787 solid Substances 0.000 description 14
239000002904 solvent Substances 0.000 description 14
208000010228 Erectile Dysfunction Diseases 0.000 description 13
230000009286 beneficial effect Effects 0.000 description 13
230000036541 health Effects 0.000 description 13
201000001881 impotence Diseases 0.000 description 13
208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
208000001613 Gambling Diseases 0.000 description 12
208000016285 Movement disease Diseases 0.000 description 12
210000004556 brain Anatomy 0.000 description 12
239000002775 capsule Substances 0.000 description 12
201000000980 schizophrenia Diseases 0.000 description 12
238000012360 testing method Methods 0.000 description 12
230000000561 anti-psychotic effect Effects 0.000 description 11
239000000935 antidepressant agent Substances 0.000 description 11
229940005513 antidepressants Drugs 0.000 description 11
230000008901 benefit Effects 0.000 description 11
230000037396 body weight Effects 0.000 description 11
229960001058 bupropion Drugs 0.000 description 11
229960003920 cocaine Drugs 0.000 description 11
239000012729 immediate-release (IR) formulation Substances 0.000 description 11
239000012071 phase Substances 0.000 description 11
201000002859 sleep apnea Diseases 0.000 description 11
239000000126 substance Substances 0.000 description 11
239000000725 suspension Substances 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
244000025254 Cannabis sativa Species 0.000 description 10
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 10
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 10
206010034158 Pathological gambling Diseases 0.000 description 10
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 10
201000010769 Prader-Willi syndrome Diseases 0.000 description 10
208000019116 sleep disease Diseases 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 10
208000024172 Cardiovascular disease Diseases 0.000 description 9
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 9
239000008186 active pharmaceutical agent Substances 0.000 description 9
239000013078 crystal Substances 0.000 description 9
230000034994 death Effects 0.000 description 9
231100000517 death Toxicity 0.000 description 9
230000001976 improved effect Effects 0.000 description 9
208000017169 kidney disease Diseases 0.000 description 9
235000020845 low-calorie diet Nutrition 0.000 description 9
239000007937 lozenge Substances 0.000 description 9
238000001228 spectrum Methods 0.000 description 9
239000007921 spray Substances 0.000 description 9
SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 8
206010006550 Bulimia nervosa Diseases 0.000 description 8
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 8
238000008214 LDL Cholesterol Methods 0.000 description 8
VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 8
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical group C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 8
201000001880 Sexual dysfunction Diseases 0.000 description 8
239000002253 acid Substances 0.000 description 8
229940049706 benzodiazepine Drugs 0.000 description 8
230000003247 decreasing effect Effects 0.000 description 8
229960001985 dextromethorphan Drugs 0.000 description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
239000003446 ligand Substances 0.000 description 8
229950002454 lysergide Drugs 0.000 description 8
238000012423 maintenance Methods 0.000 description 8
229940126403 monoamine reuptake inhibitor Drugs 0.000 description 8
210000002569 neuron Anatomy 0.000 description 8
229960001158 nortriptyline Drugs 0.000 description 8
229940127240 opiate Drugs 0.000 description 8
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 8
231100000872 sexual dysfunction Toxicity 0.000 description 8
230000007958 sleep Effects 0.000 description 8
230000037322 slow-wave sleep Effects 0.000 description 8
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 7
208000000103 Anorexia Nervosa Diseases 0.000 description 7
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 7
102000004300 GABA-A Receptors Human genes 0.000 description 7
108090000839 GABA-A Receptors Proteins 0.000 description 7
208000030990 Impulse-control disease Diseases 0.000 description 7
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
239000003263 anabolic agent Substances 0.000 description 7
230000027455 binding Effects 0.000 description 7
229940000425 combination drug Drugs 0.000 description 7
206010022437 insomnia Diseases 0.000 description 7
229960003299 ketamine Drugs 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
229940002612 prodrug Drugs 0.000 description 7
239000000651 prodrug Substances 0.000 description 7
239000000375 suspending agent Substances 0.000 description 7
JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 7
229960004751 varenicline Drugs 0.000 description 7
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 6
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 6
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 6
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 6
208000030814 Eating disease Diseases 0.000 description 6
208000019454 Feeding and Eating disease Diseases 0.000 description 6
201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 6
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 6
201000007930 alcohol dependence Diseases 0.000 description 6
230000001430 anti-depressive effect Effects 0.000 description 6
239000002585 base Substances 0.000 description 6
OFYVIGTWSQPCLF-NWDGAFQWSA-N bicifadine Chemical compound C1=CC(C)=CC=C1[C@@]1(CNC2)[C@H]2C1 OFYVIGTWSQPCLF-NWDGAFQWSA-N 0.000 description 6
229950010365 bicifadine Drugs 0.000 description 6
229940059344 chantix Drugs 0.000 description 6
229960001653 citalopram Drugs 0.000 description 6
229940127353 co-packaged product Drugs 0.000 description 6
239000013066 combination product Substances 0.000 description 6
238000009223 counseling Methods 0.000 description 6
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 6
229910052805 deuterium Inorganic materials 0.000 description 6
235000014632 disordered eating Nutrition 0.000 description 6
238000002651 drug therapy Methods 0.000 description 6
230000002526 effect on cardiovascular system Effects 0.000 description 6
239000003571 electronic cigarette Substances 0.000 description 6
238000005259 measurement Methods 0.000 description 6
229960001252 methamphetamine Drugs 0.000 description 6
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 6
206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 6
229960002296 paroxetine Drugs 0.000 description 6
229960003562 phentermine Drugs 0.000 description 6
238000012552 review Methods 0.000 description 6
239000000523 sample Substances 0.000 description 6
230000000862 serotonergic effect Effects 0.000 description 6
229960002073 sertraline Drugs 0.000 description 6
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
TWYFGYXQSYOKLK-CYUSMAIQSA-N varenicline tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 TWYFGYXQSYOKLK-CYUSMAIQSA-N 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
238000004260 weight control Methods 0.000 description 6
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 5
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 5
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 5
208000017667 Chronic Disease Diseases 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
208000002705 Glucose Intolerance Diseases 0.000 description 5
241000282412 Homo Species 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 5
208000027089 Parkinsonian disease Diseases 0.000 description 5
206010034010 Parkinsonism Diseases 0.000 description 5
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
238000007792 addition Methods 0.000 description 5
239000000164 antipsychotic agent Substances 0.000 description 5
230000003542 behavioural effect Effects 0.000 description 5
239000000969 carrier Substances 0.000 description 5
PUAQLLVFLMYYJJ-ZETCQYMHSA-N cathinone Chemical compound C[C@H](N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-ZETCQYMHSA-N 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 5
229960001042 dexmethylphenidate Drugs 0.000 description 5
235000005911 diet Nutrition 0.000 description 5
239000002270 dispersing agent Substances 0.000 description 5
230000004064 dysfunction Effects 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 5
235000019197 fats Nutrition 0.000 description 5
229960002464 fluoxetine Drugs 0.000 description 5
235000013305 food Nutrition 0.000 description 5
230000006870 function Effects 0.000 description 5
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002372 labelling Methods 0.000 description 5
XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
238000002483 medication Methods 0.000 description 5
229960001344 methylphenidate Drugs 0.000 description 5
230000001575 pathological effect Effects 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
239000002243 precursor Substances 0.000 description 5
238000011160 research Methods 0.000 description 5
238000010189 synthetic method Methods 0.000 description 5
229910052722 tritium Inorganic materials 0.000 description 5
229940018503 zyban Drugs 0.000 description 5
DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 4
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 4
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 4
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 4
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 4
102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 description 4
101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000002411 adverse Effects 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
229940070021 anabolic steroids Drugs 0.000 description 4
239000002830 appetite depressant Substances 0.000 description 4
238000013459 approach Methods 0.000 description 4
210000004227 basal ganglia Anatomy 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
230000008859 change Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
229960002896 clonidine Drugs 0.000 description 4
239000003086 colorant Substances 0.000 description 4
235000019788 craving Nutrition 0.000 description 4
230000006735 deficit Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
229960004193 dextropropoxyphene Drugs 0.000 description 4
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 4
229960002866 duloxetine Drugs 0.000 description 4
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 4
229960004341 escitalopram Drugs 0.000 description 4
229960001578 eszopiclone Drugs 0.000 description 4
239000000796 flavoring agent Substances 0.000 description 4
235000019525 fullness Nutrition 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
230000000155 isotopic effect Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229960004090 maprotiline Drugs 0.000 description 4
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 4
229960001797 methadone Drugs 0.000 description 4
SYHGEUNFJIGTRX-UHFFFAOYSA-N methylenedioxypyrovalerone Chemical compound C=1C=C2OCOC2=CC=1C(=O)C(CCC)N1CCCC1 SYHGEUNFJIGTRX-UHFFFAOYSA-N 0.000 description 4
230000036651 mood Effects 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
229960002748 norepinephrine Drugs 0.000 description 4
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
230000008520 organization Effects 0.000 description 4
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 4
230000037081 physical activity Effects 0.000 description 4
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
239000003772 serotonin uptake inhibitor Substances 0.000 description 4
208000020685 sleep-wake disease Diseases 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
201000009032 substance abuse Diseases 0.000 description 4
239000000829 suppository Substances 0.000 description 4
238000002411 thermogravimetry Methods 0.000 description 4
239000002562 thickening agent Substances 0.000 description 4
229960004688 venlafaxine Drugs 0.000 description 4
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 4
NVXPZMLRGBVYQV-WMLDXEAASA-N (1r,4s)-n-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)NC)=CC=CC=C1 NVXPZMLRGBVYQV-WMLDXEAASA-N 0.000 description 3
YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 3
SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 3
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 3
108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
244000215068 Acacia senegal Species 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
208000019901 Anxiety disease Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
244000194101 Ginkgo biloba Species 0.000 description 3
235000008100 Ginkgo biloba Nutrition 0.000 description 3
102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
229920000084 Gum arabic Polymers 0.000 description 3
206010019233 Headaches Diseases 0.000 description 3
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
102000016267 Leptin Human genes 0.000 description 3
108010092277 Leptin Proteins 0.000 description 3
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 3
MGKCAFQXBAFOSW-ACJQSPJVSA-N O=C1C(CC=C(C)C)=C(O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)CC)C2=O Chemical compound O=C1C(CC=C(C)C)=C(O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)CC)C2=O MGKCAFQXBAFOSW-ACJQSPJVSA-N 0.000 description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
206010042458 Suicidal ideation Diseases 0.000 description 3
235000010489 acacia gum Nutrition 0.000 description 3
239000000205 acacia gum Substances 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000013543 active substance Substances 0.000 description 3
RIISSLSXWPTKFE-UHFFFAOYSA-N adhyperforin Natural products CCC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O RIISSLSXWPTKFE-UHFFFAOYSA-N 0.000 description 3
238000011360 adjunctive therapy Methods 0.000 description 3
GTQLIPQFXVKRKJ-UNSMHXHVSA-N altropane Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C\C=C\I)[C@H]2C(=O)OC)=CC=C(F)C=C1 GTQLIPQFXVKRKJ-UNSMHXHVSA-N 0.000 description 3
229950004560 altropane Drugs 0.000 description 3
238000010171 animal model Methods 0.000 description 3
229940125709 anorectic agent Drugs 0.000 description 3
239000001961 anticonvulsive agent Substances 0.000 description 3
230000036506 anxiety Effects 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
229960002430 atomoxetine Drugs 0.000 description 3
VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
229960000074 biopharmaceutical Drugs 0.000 description 3
229960004596 cabergoline Drugs 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
230000002490 cerebral effect Effects 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229960003120 clonazepam Drugs 0.000 description 3
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 3
230000019771 cognition Effects 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
229940125904 compound 1 Drugs 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
239000006071 cream Substances 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 3
229960005217 dapoxetine Drugs 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
229960001623 desvenlafaxine Drugs 0.000 description 3
229960002069 diamorphine Drugs 0.000 description 3
229960003529 diazepam Drugs 0.000 description 3
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
RKUKMUWCRLRPEJ-SFHVURJKSA-N didesmethylcitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN)=CC=C(F)C=C1 RKUKMUWCRLRPEJ-SFHVURJKSA-N 0.000 description 3
230000000378 dietary effect Effects 0.000 description 3
MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 3
229960004993 dimenhydrinate Drugs 0.000 description 3
230000003292 diminished effect Effects 0.000 description 3
229960000520 diphenhydramine Drugs 0.000 description 3
OGCGXUGBDJGFFY-UHFFFAOYSA-N diphenylprolinol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1CCCN1 OGCGXUGBDJGFFY-UHFFFAOYSA-N 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
230000003291 dopaminomimetic effect Effects 0.000 description 3
235000005686 eating Nutrition 0.000 description 3
229960002179 ephedrine Drugs 0.000 description 3
230000001037 epileptic effect Effects 0.000 description 3
AIVSIRYZIBXTMM-UHFFFAOYSA-N ethylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1CCCCN1 AIVSIRYZIBXTMM-UHFFFAOYSA-N 0.000 description 3
OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 3
229950003930 femoxetine Drugs 0.000 description 3
229960001582 fenfluramine Drugs 0.000 description 3
229960004038 fluvoxamine Drugs 0.000 description 3
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 3
229960003692 gamma aminobutyric acid Drugs 0.000 description 3
239000007789 gas Substances 0.000 description 3
230000007946 glucose deprivation Effects 0.000 description 3
230000002650 habitual effect Effects 0.000 description 3
231100000869 headache Toxicity 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
235000003642 hunger Nutrition 0.000 description 3
210000003016 hypothalamus Anatomy 0.000 description 3
229950006314 ifoxetine Drugs 0.000 description 3
ZHFIAFNZGWCLHU-YPMHNXCESA-N ifoxetine Chemical compound CC1=CC=CC(O[C@@H]2[C@@H](CNCC2)O)=C1C ZHFIAFNZGWCLHU-YPMHNXCESA-N 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 3
229950002473 indalpine Drugs 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000011221 initial treatment Methods 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229940039781 leptin Drugs 0.000 description 3
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
MJJDYOLPMGIWND-UHFFFAOYSA-N litoxetine Chemical compound C=1C=C2C=CC=CC2=CC=1COC1CCNCC1 MJJDYOLPMGIWND-UHFFFAOYSA-N 0.000 description 3
229950004138 litoxetine Drugs 0.000 description 3
230000007774 longterm Effects 0.000 description 3
229960005060 lorcaserin Drugs 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229960000299 mazindol Drugs 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 3
229960000582 mepyramine Drugs 0.000 description 3
DMHQLXUFCQSQQQ-LVZFUZTISA-N mesocarb Chemical compound C=1\C(=N/C(=O)NC=2C=CC=CC=2)O[N-][N+]=1C(C)CC1=CC=CC=C1 DMHQLXUFCQSQQQ-LVZFUZTISA-N 0.000 description 3
229950010421 mesocarb Drugs 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
229960001785 mirtazapine Drugs 0.000 description 3
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 3
229960000751 nefopam Drugs 0.000 description 3
229940078420 nicotine transdermal system Drugs 0.000 description 3
ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 3
229950004211 nisoxetine Drugs 0.000 description 3
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
229960005017 olanzapine Drugs 0.000 description 3
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 3
229950005637 omiloxetine Drugs 0.000 description 3
FAHGZANUNVVDFL-HYBUGGRVSA-N omiloxetine Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](COC=2C=C3OCOC3=CC=2)CN(CC(=O)C=2C=CC(F)=CC=2)CC1 FAHGZANUNVVDFL-HYBUGGRVSA-N 0.000 description 3
229960001243 orlistat Drugs 0.000 description 3
230000007310 pathophysiology Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000002831 pharmacologic agent Substances 0.000 description 3
229940117803 phenethylamine Drugs 0.000 description 3
229960003089 pramipexole Drugs 0.000 description 3
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 3
201000009104 prediabetes syndrome Diseases 0.000 description 3
OJCPSBCUMRIPFL-UHFFFAOYSA-N prolintane Chemical compound C1CCCN1C(CCC)CC1=CC=CC=C1 OJCPSBCUMRIPFL-UHFFFAOYSA-N 0.000 description 3
229960004654 prolintane Drugs 0.000 description 3
229960003770 reboxetine Drugs 0.000 description 3
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
208000023504 respiratory system disease Diseases 0.000 description 3
230000004044 response Effects 0.000 description 3
SIIICDNNMDMWCI-YJNKXOJESA-N rti-55 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(I)C=C1 SIIICDNNMDMWCI-YJNKXOJESA-N 0.000 description 3
208000022925 sleep disturbance Diseases 0.000 description 3
239000011734 sodium Substances 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
231100000240 steatosis hepatitis Toxicity 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
210000003523 substantia nigra Anatomy 0.000 description 3
230000000153 supplemental effect Effects 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
229950001671 tametraline Drugs 0.000 description 3
KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 3
229960005126 tapentadol Drugs 0.000 description 3
OILWWIVKIDXCIB-UHFFFAOYSA-N teniloxazine Chemical compound C1NCCOC1COC1=CC=CC=C1CC1=CC=CS1 OILWWIVKIDXCIB-UHFFFAOYSA-N 0.000 description 3
229950003014 teniloxazine Drugs 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
208000002271 trichotillomania Diseases 0.000 description 3
210000003932 urinary bladder Anatomy 0.000 description 3
229960001255 viloxazine Drugs 0.000 description 3
ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 3
229960001475 zolpidem Drugs 0.000 description 3
DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
PTJADDMMFYXMMG-LJQANCHMSA-N (1r)-1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-3h-2-benzofuran-5-carbonitrile Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCNC)=CC=C(F)C=C1 PTJADDMMFYXMMG-LJQANCHMSA-N 0.000 description 2
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
AHOUBRCZNHFOSL-SVLNYFRSSA-N (3s,4r)-3-[(2,2-dideuterio-1,3-benzodioxol-5-yl)oxymethyl]-4-(4-fluorophenyl)piperidine Chemical compound C1([C@@H]2CCNC[C@H]2COC2=CC=C3OC(OC3=C2)([2H])[2H])=CC=C(F)C=C1 AHOUBRCZNHFOSL-SVLNYFRSSA-N 0.000 description 2
WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 2
SQEBMLCQNJOCBG-HVHJFMEUSA-N (5s)-3-(hydroxymethyl)-5-methoxy-4-methyl-5-[(e)-2-phenylethenyl]furan-2-one Chemical compound C=1C=CC=CC=1/C=C/[C@]1(OC)OC(=O)C(CO)=C1C SQEBMLCQNJOCBG-HVHJFMEUSA-N 0.000 description 2
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
NTJQREUGJKIARY-UHFFFAOYSA-N 1-(2,5-dimethoxy-4-methylphenyl)propan-2-amine Chemical compound COC1=CC(CC(C)N)=C(OC)C=C1C NTJQREUGJKIARY-UHFFFAOYSA-N 0.000 description 2
VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 2
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 2
NFTOEHBFQROATQ-UHFFFAOYSA-N 2,3-dihydrofuran-5-carboxylic acid Chemical compound OC(=O)C1=CCCO1 NFTOEHBFQROATQ-UHFFFAOYSA-N 0.000 description 2
GVCTYSKUHKXJDZ-IUCAKERBSA-N 2-[[(2s)-3-(1h-imidazol-5-yl)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]acetic acid Chemical compound C([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H]1NC(=O)CC1)C1=CN=CN1 GVCTYSKUHKXJDZ-IUCAKERBSA-N 0.000 description 2
FZSPJBYOKQPKCD-UHFFFAOYSA-N 2-aminopropanoic acid [1-(4-chlorophenyl)-2-methylpropan-2-yl] ester Chemical compound CC(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-UHFFFAOYSA-N 0.000 description 2
WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 2
SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
BQDUNOMMYOKHEP-GQALSZNTSA-N 3-(2,5-difluorophenyl)-7-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound N12N=C(OCC=3N(N=CN=3)C)C(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=CC2=NN=C1C1=CC(F)=CC=C1F BQDUNOMMYOKHEP-GQALSZNTSA-N 0.000 description 2
IKBZAUYPBWFMDI-UHFFFAOYSA-N 5-bromo-4-methoxy-7-methyl-2,3-dihydro-1h-indene Chemical compound C1=C(Br)C(OC)=C2CCCC2=C1C IKBZAUYPBWFMDI-UHFFFAOYSA-N 0.000 description 2
208000030090 Acute Disease Diseases 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
206010002820 Antisocial behaviour Diseases 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
206010003805 Autism Diseases 0.000 description 2
208000020706 Autistic disease Diseases 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 2
ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 2
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
206010010774 Constipation Diseases 0.000 description 2
206010052895 Coronary artery insufficiency Diseases 0.000 description 2
229920000832 Cutin Polymers 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
101150049660 DRD2 gene Proteins 0.000 description 2
JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 2
FBMORZZOJSDNRQ-UHFFFAOYSA-N Demethoxy,B,HCl-Adriamycin Natural products C1C2C(=C)CCCC2(C)CC2(O)C1=C(C)C(=O)O2 FBMORZZOJSDNRQ-UHFFFAOYSA-N 0.000 description 2
102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 2
OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
208000018522 Gastrointestinal disease Diseases 0.000 description 2
102000051325 Glucagon Human genes 0.000 description 2
108060003199 Glucagon Proteins 0.000 description 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
206010018429 Glucose tolerance impaired Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000034308 Grand mal convulsion Diseases 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
206010020710 Hyperphagia Diseases 0.000 description 2
201000001916 Hypochondriasis Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010022489 Insulin Resistance Diseases 0.000 description 2
108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 2
101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 2
IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 2
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
229940123257 Opioid receptor antagonist Drugs 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
208000037158 Partial Epilepsies Diseases 0.000 description 2
206010061334 Partial seizures Diseases 0.000 description 2
102100029909 Peptide YY Human genes 0.000 description 2
108010088847 Peptide YY Proteins 0.000 description 2
MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
238000010357 RNA editing Methods 0.000 description 2
230000026279 RNA modification Effects 0.000 description 2
241000700159 Rattus Species 0.000 description 2
ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 2
241000555745 Sciuridae Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 description 2
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
208000000323 Tourette Syndrome Diseases 0.000 description 2
208000016620 Tourette disease Diseases 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001299 aldehydes Chemical group 0.000 description 2
229960001391 alfentanil Drugs 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
229960004538 alprazolam Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
230000001773 anti-convulsant effect Effects 0.000 description 2
229940127088 antihypertensive drug Drugs 0.000 description 2
208000024823 antisocial personality disease Diseases 0.000 description 2
HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
229960001264 benfluorex Drugs 0.000 description 2
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
CJAVTWRYCDNHSM-UHFFFAOYSA-N benzoic acid 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl ester Chemical compound C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 description 2
YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 2
229960002837 benzphetamine Drugs 0.000 description 2
208000022266 body dysmorphic disease Diseases 0.000 description 2
229960002802 bromocriptine Drugs 0.000 description 2
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
229960004367 bupropion hydrochloride Drugs 0.000 description 2
229960001948 caffeine Drugs 0.000 description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
229960001713 canagliflozin Drugs 0.000 description 2
VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 2
230000007211 cardiovascular event Effects 0.000 description 2
YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 description 2
229950004689 carfentanil Drugs 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 2
229950002397 cetilistat Drugs 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
208000020832 chronic kidney disease Diseases 0.000 description 2
229960004606 clomipramine Drugs 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
229960004126 codeine Drugs 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
229960003834 dapagliflozin Drugs 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
SRPXSILJHWNFMK-ZBEGNZNMSA-N desmethylsertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-ZBEGNZNMSA-N 0.000 description 2
229960000632 dexamfetamine Drugs 0.000 description 2
229960004597 dexfenfluramine Drugs 0.000 description 2
239000012954 diazonium Substances 0.000 description 2
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 2
229960004890 diethylpropion Drugs 0.000 description 2
XSYGBVSQKPLETJ-ANULTFPQSA-N difluoropine Chemical compound O([C@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 XSYGBVSQKPLETJ-ANULTFPQSA-N 0.000 description 2
229960000920 dihydrocodeine Drugs 0.000 description 2
RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 2
229960004192 diphenoxylate Drugs 0.000 description 2
238000009826 distribution Methods 0.000 description 2
208000002173 dizziness Diseases 0.000 description 2
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 2
239000000890 drug combination Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000007876 drug discovery Methods 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
206010013781 dry mouth Diseases 0.000 description 2
CPBHSHYQQLFAPW-ZWKOTPCHSA-N edivoxetine Chemical compound COC1=CC=C(F)C=C1C[C@](O)([C@H]1OCCNC1)C1CCOCC1 CPBHSHYQQLFAPW-ZWKOTPCHSA-N 0.000 description 2
229950003015 edivoxetine Drugs 0.000 description 2
229960003345 empagliflozin Drugs 0.000 description 2
OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
150000002148 esters Chemical group 0.000 description 2
229960004578 ethylmorphine Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000013213 extrapolation Methods 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
230000004634 feeding behavior Effects 0.000 description 2
PDTADBTVZXKSJM-UHFFFAOYSA-N fencamine Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C)C=1NCCN(C)C(C)CC1=CC=CC=C1 PDTADBTVZXKSJM-UHFFFAOYSA-N 0.000 description 2
229960002428 fentanyl Drugs 0.000 description 2
IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 2
229960001751 fluoxymesterone Drugs 0.000 description 2
201000007186 focal epilepsy Diseases 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
208000020694 gallbladder disease Diseases 0.000 description 2
230000000574 ganglionic effect Effects 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
229960004666 glucagon Drugs 0.000 description 2
108091005995 glycated hemoglobin Proteins 0.000 description 2
230000002641 glycemic effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000008821 health effect Effects 0.000 description 2
208000018578 heart valve disease Diseases 0.000 description 2
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
229960000240 hydrocodone Drugs 0.000 description 2
150000002483 hydrogen compounds Chemical class 0.000 description 2
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
229960001410 hydromorphone Drugs 0.000 description 2
IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 2
QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000011283 initial treatment period Methods 0.000 description 2
229940102223 injectable solution Drugs 0.000 description 2
230000010354 integration Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
229950000991 ipragliflozin Drugs 0.000 description 2
AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 2
IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 2
JUTMAMXOAOYKHT-UHFFFAOYSA-N karrikinolide Natural products C1=COC=C2OC(=O)C(C)=C21 JUTMAMXOAOYKHT-UHFFFAOYSA-N 0.000 description 2
150000002576 ketones Chemical group 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000011813 knockout mouse model Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
150000002596 lactones Chemical group 0.000 description 2
229960003406 levorphanol Drugs 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
244000144972 livestock Species 0.000 description 2
229960004391 lorazepam Drugs 0.000 description 2
239000006210 lotion Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
229960001566 methyltestosterone Drugs 0.000 description 2
229940059619 mg plus protein Drugs 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000000407 monoamine reuptake Effects 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
230000008450 motivation Effects 0.000 description 2
SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 2
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
229960003086 naltrexone Drugs 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
230000008693 nausea Effects 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
239000002547 new drug Substances 0.000 description 2
229940087730 nicorette Drugs 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
210000001009 nucleus accumben Anatomy 0.000 description 2
229940126701 oral medication Drugs 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
235000006408 oxalic acid Nutrition 0.000 description 2
229960000321 oxolinic acid Drugs 0.000 description 2
229960002085 oxycodone Drugs 0.000 description 2
229960001528 oxymetazoline Drugs 0.000 description 2
229960005118 oxymorphone Drugs 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
239000006201 parenteral dosage form Substances 0.000 description 2
230000001314 paroxysmal effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
229960000482 pethidine Drugs 0.000 description 2
229960000897 phenazocine Drugs 0.000 description 2
ZQHYKVKNPWDQSL-KNXBSLHKSA-N phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 description 2
229960000436 phendimetrazine Drugs 0.000 description 2
229960003209 phenmetrazine Drugs 0.000 description 2
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
229960000395 phenylpropanolamine Drugs 0.000 description 2
239000006187 pill Substances 0.000 description 2
PXXKIYPSXYFATG-UHFFFAOYSA-N piminodine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCCNC1=CC=CC=C1 PXXKIYPSXYFATG-UHFFFAOYSA-N 0.000 description 2
229950006445 piminodine Drugs 0.000 description 2
229960005095 pioglitazone Drugs 0.000 description 2
229950007239 pirandamine Drugs 0.000 description 2
AMJPIGOYWBNJLP-UHFFFAOYSA-N pirandamine Chemical compound C1C2=CC=CC=C2C2=C1C(CCN(C)C)(C)OCC2 AMJPIGOYWBNJLP-UHFFFAOYSA-N 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
208000028173 post-traumatic stress disease Diseases 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
238000000634 powder X-ray diffraction Methods 0.000 description 2
229960003611 pramlintide Drugs 0.000 description 2
108010029667 pramlintide Proteins 0.000 description 2
NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000003380 propellant Substances 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
229960003908 pseudoephedrine Drugs 0.000 description 2
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 2
230000001107 psychogenic effect Effects 0.000 description 2
230000005180 public health Effects 0.000 description 2
108010022711 pyroglutamyl-histidyl-glycine Proteins 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
235000018770 reduced food intake Nutrition 0.000 description 2
229960003394 remifentanil Drugs 0.000 description 2
229950011516 remogliflozin etabonate Drugs 0.000 description 2
UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
229960004586 rosiglitazone Drugs 0.000 description 2
238000012216 screening Methods 0.000 description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
231100000489 sensitizer Toxicity 0.000 description 2
229940126570 serotonin reuptake inhibitor Drugs 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
229960004425 sibutramine Drugs 0.000 description 2
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000007863 steatosis Effects 0.000 description 2
231100000736 substance abuse Toxicity 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229960004739 sufentanil Drugs 0.000 description 2
GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 2
230000001629 suppression Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229960003604 testosterone Drugs 0.000 description 2
210000001103 thalamus Anatomy 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229950006667 tofogliflozin Drugs 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
229960004394 topiramate Drugs 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
229960003991 trazodone Drugs 0.000 description 2
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
230000001755 vocal effect Effects 0.000 description 2
239000001993 wax Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
229960002911 zonisamide Drugs 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
LTHJBDQSFIGMAZ-UHFFFAOYSA-N (1-phenyl-4-bicyclo[2.2.2]octanyl)azanium;chloride Chemical compound [Cl-].C1CC([NH3+])(CC2)CCC12C1=CC=CC=C1 LTHJBDQSFIGMAZ-UHFFFAOYSA-N 0.000 description 1
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
JNHPUZURWFYYHW-DTUSRQQPSA-N (1R,2S,6R,14R,15R,19R)-19-[(2R)-2-hydroxypentan-2-yl]-15-methoxy-5-methyl-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,16-tetraen-11-ol hydrochloride Chemical compound Cl.O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O JNHPUZURWFYYHW-DTUSRQQPSA-N 0.000 description 1
IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
RZFGPAMUAXASRE-YSZCXEEOSA-N (3r,5s,8r,9s,10r,13s,14s,17s)-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound C1[C@@H](O)C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 RZFGPAMUAXASRE-YSZCXEEOSA-N 0.000 description 1
FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
GRUIIAQNNWQJPW-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-(4-methylpiperazin-1-yl)ethyl]cyclohexan-1-ol Chemical compound C1CN(C)CCN1CC(C1(O)CCCCC1)C1=CC=CC(Cl)=C1 GRUIIAQNNWQJPW-UHFFFAOYSA-N 0.000 description 1
RAQPOZGWANIDQT-UHFFFAOYSA-N 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCN(CC1)CCN1CCOC(C=1C=CC=CC=1)C1=CC=CC=C1 RAQPOZGWANIDQT-UHFFFAOYSA-N 0.000 description 1
RZFGPAMUAXASRE-UHFFFAOYSA-N 1-androstenediol Natural products C1C(O)C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC21 RZFGPAMUAXASRE-UHFFFAOYSA-N 0.000 description 1
WJIQCDPCDVWDDE-UHFFFAOYSA-N 1-androstenedione Natural products C1C(=O)C=CC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 WJIQCDPCDVWDDE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical compound CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 description 1
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
QCWCXSMWLJFBNM-FOVYBZIDSA-N 17beta-Hydroxy-2alpha,17-dimethyl-5alpha-androstan-3-one Chemical compound C1C[C@@H]2[C@@]3(C)C[C@@H](C)C(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@](C)(O)[C@]21C QCWCXSMWLJFBNM-FOVYBZIDSA-N 0.000 description 1
JRIZOGLBRPZBLQ-QXUSFIETSA-N 19-Norandrostenedione Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JRIZOGLBRPZBLQ-QXUSFIETSA-N 0.000 description 1
YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
SGVQMKDQDTWFEM-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-(chloroamino)benzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=C(NCl)C=C1 SGVQMKDQDTWFEM-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
SUXGNJVVBGJEFB-UHFFFAOYSA-N 25b-nbome Chemical compound COC1=CC=CC=C1CNCCC1=CC(OC)=C(Br)C=C1OC SUXGNJVVBGJEFB-UHFFFAOYSA-N 0.000 description 1
FJFPOGCVVLUYAQ-UHFFFAOYSA-N 25c-nbome Chemical compound COC1=CC=CC=C1CNCCC1=CC(OC)=C(Cl)C=C1OC FJFPOGCVVLUYAQ-UHFFFAOYSA-N 0.000 description 1
CGKQFIWIPSIVAS-UHFFFAOYSA-N 2c-c Chemical compound COC1=CC(CCN)=C(OC)C=C1Cl CGKQFIWIPSIVAS-UHFFFAOYSA-N 0.000 description 1
VDRGNAMREYBIHA-UHFFFAOYSA-N 2c-e Chemical compound CCC1=CC(OC)=C(CCN)C=C1OC VDRGNAMREYBIHA-UHFFFAOYSA-N 0.000 description 1
PQHQBRJAAZQXHL-UHFFFAOYSA-N 2c-i Chemical compound COC1=CC(CCN)=C(OC)C=C1I PQHQBRJAAZQXHL-UHFFFAOYSA-N 0.000 description 1
ZMUSDZGRRJGRAO-UHFFFAOYSA-N 2c-n Chemical compound COC1=CC([N+]([O-])=O)=C(OC)C=C1CCN ZMUSDZGRRJGRAO-UHFFFAOYSA-N 0.000 description 1
PZJOKFZGPTVNBF-UHFFFAOYSA-N 2c-p Chemical compound CCCC1=CC(OC)=C(CCN)C=C1OC PZJOKFZGPTVNBF-UHFFFAOYSA-N 0.000 description 1
LGUVDOBGXUFUAJ-UHFFFAOYSA-N 2c-t-19 Chemical compound CCCCSC1=CC(OC)=C(CCN)C=C1OC LGUVDOBGXUFUAJ-UHFFFAOYSA-N 0.000 description 1
HCWQGDLBIKOJPM-UHFFFAOYSA-N 2c-t-2 Chemical compound CCSC1=CC(OC)=C(CCN)C=C1OC HCWQGDLBIKOJPM-UHFFFAOYSA-N 0.000 description 1
ZBUUUKBTOCTOPW-UHFFFAOYSA-N 2c-t-21 Chemical compound COC1=CC(SCCF)=C(OC)C=C1CCN ZBUUUKBTOCTOPW-UHFFFAOYSA-N 0.000 description 1
HDYZSVKZKDPLDT-UHFFFAOYSA-N 2c-t-4 Chemical compound COC1=CC(SC(C)C)=C(OC)C=C1CCN HDYZSVKZKDPLDT-UHFFFAOYSA-N 0.000 description 1
OLEVEPDJOFPJTF-UHFFFAOYSA-N 2c-t-7 Chemical compound CCCSC1=CC(OC)=C(CCN)C=C1OC OLEVEPDJOFPJTF-UHFFFAOYSA-N 0.000 description 1
AHMSSHCYIDBVQB-UHFFFAOYSA-N 2c-t-8 Chemical compound C1=C(CCN)C(OC)=CC(SCC2CC2)=C1OC AHMSSHCYIDBVQB-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
BQOIJSIMMIDHMO-FBPKJDBXSA-N 4-Hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O BQOIJSIMMIDHMO-FBPKJDBXSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
TUYBQKUONKIYCN-UHFFFAOYSA-N 4-amino-2-[2-(diethylamino)ethyl]benzoic acid Chemical compound CCN(CC)CCC1=CC(N)=CC=C1C(O)=O TUYBQKUONKIYCN-UHFFFAOYSA-N 0.000 description 1
APTIFBSTEIXFOB-UHFFFAOYSA-N 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC(F)=CC=C2NC(=O)CN=C1C1=CC=CC=C1Br APTIFBSTEIXFOB-UHFFFAOYSA-N 0.000 description 1
VKUMKUZDZWHMQU-UHFFFAOYSA-N 5-APB Chemical compound CC(N)CC1=CC=C2OC=CC2=C1 VKUMKUZDZWHMQU-UHFFFAOYSA-N 0.000 description 1
XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
WJIQCDPCDVWDDE-WZNAKSSCSA-N 5alpha-androst-1-ene-3,17-dione Chemical compound C1C(=O)C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 WJIQCDPCDVWDDE-WZNAKSSCSA-N 0.000 description 1
FQDAMYLMQQKPRX-UHFFFAOYSA-N 6-apb Chemical compound CC(N)CC1=CC=C2C=COC2=C1 FQDAMYLMQQKPRX-UHFFFAOYSA-N 0.000 description 1
CGMJQQJSWIRRRL-UHFFFAOYSA-N 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound ClC1=CC=CC=C1C1=NCC(=O)NC2=CC=C(Br)C=C12 CGMJQQJSWIRRRL-UHFFFAOYSA-N 0.000 description 1
XBWAZCLHZCFCGK-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3,4-dihydro-2h-1,4-benzodiazepin-1-ium;chloride Chemical compound [Cl-].C12=CC(Cl)=CC=C2[NH+](C)CCN=C1C1=CC=CC=C1 XBWAZCLHZCFCGK-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
KCEIOBKDDQAYCM-UHFFFAOYSA-N 8-bromo-1-methyl-6-phenyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine Chemical compound C12=CC(Br)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 KCEIOBKDDQAYCM-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
208000004611 Abdominal Obesity Diseases 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
206010000117 Abnormal behaviour Diseases 0.000 description 1
206010000125 Abnormal dreams Diseases 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 1
206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
206010002942 Apathy Diseases 0.000 description 1
CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
244000187129 Bacopa monnieria Species 0.000 description 1
235000015418 Bacopa monnieria Nutrition 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000015879 Cerebellar disease Diseases 0.000 description 1
240000000425 Chaenomeles speciosa Species 0.000 description 1
235000005078 Chaenomeles speciosa Nutrition 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
208000027691 Conduct disease Diseases 0.000 description 1
108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
OKJCFMUGMSVJBG-ABEVXSGRSA-N Delta(1)-dihydrotestosterone Chemical compound C1C(=O)C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OKJCFMUGMSVJBG-ABEVXSGRSA-N 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
206010012374 Depressed mood Diseases 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
206010013700 Drug hypersensitivity Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
208000037579 Eating reflex epilepsy Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010049119 Emotional distress Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010015535 Euphoric mood Diseases 0.000 description 1
208000027776 Extrapyramidal disease Diseases 0.000 description 1
208000004930 Fatty Liver Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010057671 Female sexual dysfunction Diseases 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
208000001836 Firesetting Behavior Diseases 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
OFVXPDXXVSGEPX-UHFFFAOYSA-N Flutoprazepam Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C11)=NCC(=O)N1CC1CC1 OFVXPDXXVSGEPX-UHFFFAOYSA-N 0.000 description 1
208000010235 Food Addiction Diseases 0.000 description 1
206010056465 Food craving Diseases 0.000 description 1
206010017918 Gastroenteritis viral Diseases 0.000 description 1
208000003078 Generalized Epilepsy Diseases 0.000 description 1
BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 1
235000011201 Ginkgo Nutrition 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010019708 Hepatic steatosis Diseases 0.000 description 1
206010020400 Hostility Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
229940123993 Incretin mimetic Drugs 0.000 description 1
206010021750 Infantile Spasms Diseases 0.000 description 1
208000035899 Infantile spasms syndrome Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
201000006347 Intellectual Disability Diseases 0.000 description 1
208000005168 Intussusception Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
238000003109 Karl Fischer titration Methods 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
229940127470 Lipase Inhibitors Drugs 0.000 description 1
229940086609 Lipase inhibitor Drugs 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010057672 Male sexual dysfunction Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000001796 Melanocortin 4 receptors Human genes 0.000 description 1
101710151321 Melanostatin Proteins 0.000 description 1
WYZDXEKUWRCKOB-YDSAWKJFSA-N Mestanolone Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 WYZDXEKUWRCKOB-YDSAWKJFSA-N 0.000 description 1
RDJBOAMEIJEKEY-XWSJACJDSA-N Methyldienolone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 RDJBOAMEIJEKEY-XWSJACJDSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000007379 Muscle Hypotonia Diseases 0.000 description 1
208000036572 Myoclonic epilepsy Diseases 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
102400000064 Neuropeptide Y Human genes 0.000 description 1
ZXSWTMLNIIZPET-ZOFHRBRSSA-N Normethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 ZXSWTMLNIIZPET-ZOFHRBRSSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
206010057342 Onychophagia Diseases 0.000 description 1
239000008896 Opium Substances 0.000 description 1
ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 description 1
ZKLXUUYLEHCAMF-UHFFFAOYSA-N Oripavine Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(O)C5=C4C23C1O5 ZKLXUUYLEHCAMF-UHFFFAOYSA-N 0.000 description 1
QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
102000019280 Pancreatic lipases Human genes 0.000 description 1
108050006759 Pancreatic lipases Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010037180 Psychiatric symptoms Diseases 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
206010057430 Retinal injury Diseases 0.000 description 1
235000011034 Rubus glaucus Nutrition 0.000 description 1
244000235659 Rubus idaeus Species 0.000 description 1
235000009122 Rubus idaeus Nutrition 0.000 description 1
206010048908 Seasonal allergy Diseases 0.000 description 1
229940127347 Serotonin 2c Receptor Agonists Drugs 0.000 description 1
208000020221 Short stature Diseases 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
206010065604 Suicidal behaviour Diseases 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 1
102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 1
CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
OXHNQTSIKGHVBH-ANULTFPQSA-N Tetrahydrogestrinone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(CC)C=C2 OXHNQTSIKGHVBH-ANULTFPQSA-N 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
208000006633 Tonic-Clonic Epilepsy Diseases 0.000 description 1
QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
229920000027 Valéron Polymers 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
201000006791 West syndrome Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
238000001467 acupuncture Methods 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229940124533 adjunct drug Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
229960000959 amineptine Drugs 0.000 description 1
VDPUXONTAVMIKZ-UHFFFAOYSA-N amineptine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2C([NH2+]CCCCCCC(=O)O)C2=CC=CC=C21 VDPUXONTAVMIKZ-UHFFFAOYSA-N 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
229960002519 amoxapine Drugs 0.000 description 1
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 1
229960003473 androstanolone Drugs 0.000 description 1
229950009148 androstenediol Drugs 0.000 description 1
229960005471 androstenedione Drugs 0.000 description 1
AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003579 anti-obesity Effects 0.000 description 1
230000002426 anti-panic effect Effects 0.000 description 1
230000002738 anti-smoking effect Effects 0.000 description 1
230000002180 anti-stress Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940125710 antiobesity agent Drugs 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229960004372 aripiprazole Drugs 0.000 description 1
150000004982 aromatic amines Chemical class 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000013475 authorization Methods 0.000 description 1
235000021053 average weight gain Nutrition 0.000 description 1
150000001538 azepines Chemical class 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
229950009087 bifeprunox Drugs 0.000 description 1
208000014679 binge eating disease Diseases 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
208000024330 bloating Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
229950007271 boldenone Drugs 0.000 description 1
230000005978 brain dysfunction Effects 0.000 description 1
LWUDDYHYYNNIQI-ZDUSSCGKSA-N bretazenil Chemical compound O=C1C2=C(Br)C=CC=C2N2C=NC(C(=O)OC(C)(C)C)=C2[C@@H]2CCCN21 LWUDDYHYYNNIQI-ZDUSSCGKSA-N 0.000 description 1
229950010832 bretazenil Drugs 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
229960003051 brotizolam Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
229960002495 buspirone Drugs 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
229960001113 butorphanol Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
229950009823 calusterone Drugs 0.000 description 1
QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
229950011318 cannabidiol Drugs 0.000 description 1
229960003453 cannabinol Drugs 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
229950002698 cathinone Drugs 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
229960004782 chlordiazepoxide Drugs 0.000 description 1
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
229950007046 chlorphentermine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
210000002932 cholinergic neuron Anatomy 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
235000019506 cigar Nutrition 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
229960001403 clobazam Drugs 0.000 description 1
KCZCIYZKSLLNNH-FBPKJDBXSA-N clostebol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1Cl KCZCIYZKSLLNNH-FBPKJDBXSA-N 0.000 description 1
229960001481 clostebol Drugs 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000000306 component Substances 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
208000012696 congenital leptin deficiency Diseases 0.000 description 1
230000037020 contractile activity Effects 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
229960003572 cyclobenzaprine Drugs 0.000 description 1
101150112582 dad2 gene Proteins 0.000 description 1
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
229960000766 danazol Drugs 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
CHIFCDOIPRCHCF-UHFFFAOYSA-N delorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl CHIFCDOIPRCHCF-UHFFFAOYSA-N 0.000 description 1
229950007393 delorazepam Drugs 0.000 description 1
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
238000001739 density measurement Methods 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 description 1
229960003701 dextromoramide Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229960003461 dezocine Drugs 0.000 description 1
VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
150000001989 diazonium salts Chemical class 0.000 description 1
229960005215 dichloroacetic acid Drugs 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
BRTSNYPDACNMIP-FAWZKKEFSA-N dihydroetorphine Chemical compound O([C@H]1[C@@]2(OC)CC[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O BRTSNYPDACNMIP-FAWZKKEFSA-N 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000000221 dopamine uptake inhibitor Substances 0.000 description 1
210000002108 dorsomedial hypothalamic nucleus Anatomy 0.000 description 1
BSMNRYCSBFHEMQ-UHFFFAOYSA-N dov-216,303 Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(CNC2)C2C1 BSMNRYCSBFHEMQ-UHFFFAOYSA-N 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229960005426 doxepin Drugs 0.000 description 1
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
229960004242 dronabinol Drugs 0.000 description 1
238000009510 drug design Methods 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
230000005584 early death Effects 0.000 description 1
201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
229910052571 earthenware Inorganic materials 0.000 description 1
208000024239 eating seizures Diseases 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000006397 emotional response Effects 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
238000005265 energy consumption Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
201000002933 epilepsy with generalized tonic-clonic seizures Diseases 0.000 description 1
230000008579 epileptogenesis Effects 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
230000002743 euphoric effect Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
239000002360 explosive Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
206010016165 failure to thrive Diseases 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
208000010706 fatty liver disease Diseases 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
229960004381 flumazenil Drugs 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229960003528 flurazepam Drugs 0.000 description 1
SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
229950009299 flutoprazepam Drugs 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
229960004761 gestrinone Drugs 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
229940087496 habitrol Drugs 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
229960002158 halazepam Drugs 0.000 description 1
230000007407 health benefit Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
125000005241 heteroarylamino group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000002017 high-resolution X-ray diffraction Methods 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
150000003840 hydrochlorides Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
239000000864 hyperglycemic agent Substances 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
239000000859 incretin Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
230000030214 innervation Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000006303 iodophenyl group Chemical group 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960002672 isocarboxazid Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229950009272 isomethadone Drugs 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
PWAJCNITSBZRBL-UHFFFAOYSA-N ketazolam Chemical compound O1C(C)=CC(=O)N2CC(=O)N(C)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1 PWAJCNITSBZRBL-UHFFFAOYSA-N 0.000 description 1
229960004423 ketazolam Drugs 0.000 description 1
206010023461 kleptomania Diseases 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000010410 layer Substances 0.000 description 1
150000002611 lead compounds Chemical class 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000006742 locomotor activity Effects 0.000 description 1
UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 1
229960003019 loprazolam Drugs 0.000 description 1
229960004033 lormetazepam Drugs 0.000 description 1
229950004863 lortalamine Drugs 0.000 description 1
MJRPHRMGEKCADU-JVLSTEMRSA-N lortalamine Chemical compound C12=CC(Cl)=CC=C2O[C@]23CCN(C)C[C@@H]2[C@H]1CC(=O)N3 MJRPHRMGEKCADU-JVLSTEMRSA-N 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
GHFGJTVYMNRGBY-UHFFFAOYSA-N m-tyramine Chemical compound NCCC1=CC=CC(O)=C1 GHFGJTVYMNRGBY-UHFFFAOYSA-N 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229940098895 maleic acid Drugs 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 description 1
229960002225 medazepam Drugs 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
229960000365 meptazinol Drugs 0.000 description 1
229950008604 mestanolone Drugs 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 description 1
229950009131 metazocine Drugs 0.000 description 1
229960003578 metenolone Drugs 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
ANJQEDFWRSLVBR-VHUDCFPWSA-N methenolone Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C ANJQEDFWRSLVBR-VHUDCFPWSA-N 0.000 description 1
NEHPFNBRZYFWFN-UHFFFAOYSA-N methyl 2-cyclopentyl-2-(3,4-dichlorophenyl)acetate Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)OC)C1CCCC1 NEHPFNBRZYFWFN-UHFFFAOYSA-N 0.000 description 1
GADIKQPUNWAMEB-UHFFFAOYSA-N methyl 4-ethyl-6,7-dimethoxy-9H-pyrido[5,4-b]indole-3-carboxylate Chemical compound N1C2=CC(OC)=C(OC)C=C2C2=C1C=NC(C(=O)OC)=C2CC GADIKQPUNWAMEB-UHFFFAOYSA-N 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
229960000270 methylestrenolone Drugs 0.000 description 1
229950006489 mibolerone Drugs 0.000 description 1
PTQMMNYJKCSPET-OMHQDGTGSA-N mibolerone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 PTQMMNYJKCSPET-OMHQDGTGSA-N 0.000 description 1
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
229960003793 midazolam Drugs 0.000 description 1
229960000600 milnacipran Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
230000001730 monoaminergic effect Effects 0.000 description 1
208000001022 morbid obesity Diseases 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
229940051866 mouthwash Drugs 0.000 description 1
230000000510 mucolytic effect Effects 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
MYWUZJCMWCOHBA-UHFFFAOYSA-N n-methyl-1-phenylpropan-2-amine Chemical compound CNC(C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-UHFFFAOYSA-N 0.000 description 1
229960000805 nalbuphine Drugs 0.000 description 1
NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
229960004719 nandrolone Drugs 0.000 description 1
NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
229960001800 nefazodone Drugs 0.000 description 1
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000009907 neuroendocrine response Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000003955 neuronal function Effects 0.000 description 1
229940099632 nicotrol Drugs 0.000 description 1
GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
229950001981 nimetazepam Drugs 0.000 description 1
KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
229960001454 nitrazepam Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229960001073 nomifensine Drugs 0.000 description 1
XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 1
AKPLHCDWDRPJGD-UHFFFAOYSA-N nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
229960002640 nordazepam Drugs 0.000 description 1
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
LRCXRAABFLIVAI-UHFFFAOYSA-N norfenefrine Chemical compound NCC(O)C1=CC=CC(O)=C1 LRCXRAABFLIVAI-UHFFFAOYSA-N 0.000 description 1
229960001856 norfenefrine Drugs 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
229960001576 octopamine Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000003401 opiate antagonist Substances 0.000 description 1
229960001027 opium Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
229960000464 oxandrolone Drugs 0.000 description 1
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
229960004535 oxazepam Drugs 0.000 description 1
DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
229960005244 oxymetholone Drugs 0.000 description 1
ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
229940116369 pancreatic lipase Drugs 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
229940055726 pantothenic acid Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008775 paternal effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
230000018052 penile erection Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
229940049721 phenazepam Drugs 0.000 description 1
OOBHFESNSZDWIU-UHFFFAOYSA-N phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
208000024335 physical disease Diseases 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
MFZOSKPPVCIFMT-UHFFFAOYSA-N pinazepam Chemical compound C12=CC(Cl)=CC=C2N(CC#C)C(=O)CN=C1C1=CC=CC=C1 MFZOSKPPVCIFMT-UHFFFAOYSA-N 0.000 description 1
229960002034 pinazepam Drugs 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000003234 polygenic effect Effects 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
206010036596 premature ejaculation Diseases 0.000 description 1
CNWSHOJSFGGNLC-UHFFFAOYSA-N premazepam Chemical compound C=1N(C)C(C)=C2C=1NC(=O)CN=C2C1=CC=CC=C1 CNWSHOJSFGGNLC-UHFFFAOYSA-N 0.000 description 1
229950003432 premazepam Drugs 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
230000002206 pro-fibrotic effect Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
229960002601 protriptyline Drugs 0.000 description 1
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
BGRWSFIQQPVEML-UHFFFAOYSA-N pyrazolam Chemical compound C12=CC(Br)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=N1 BGRWSFIQQPVEML-UHFFFAOYSA-N 0.000 description 1
201000004645 pyromania Diseases 0.000 description 1
SWUVZKWCOBGPTH-UHFFFAOYSA-N pyrovalerone Chemical compound C=1C=C(C)C=CC=1C(=O)C(CCC)N1CCCC1 SWUVZKWCOBGPTH-UHFFFAOYSA-N 0.000 description 1
229950010600 pyrovalerone Drugs 0.000 description 1
229960004431 quetiapine Drugs 0.000 description 1
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
229950011009 racemorphan Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
210000001609 raphe nuclei Anatomy 0.000 description 1
230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000029556 regulation of feeding behavior Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
208000017443 reproductive system disease Diseases 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
BKTTWZADZNUOBW-UHFFFAOYSA-N roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 description 1
229950000366 roxindole Drugs 0.000 description 1
BSMPOYNWUIFFDN-XNISGKROSA-N rti-353 Chemical compound C1=C(I)C(CC)=CC=C1[C@@H]1[C@H](C(=O)OC)[C@H](N2)CC[C@H]2C1 BSMPOYNWUIFFDN-XNISGKROSA-N 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
229960003946 selegiline Drugs 0.000 description 1
230000035807 sensation Effects 0.000 description 1
235000019615 sensations Nutrition 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000003723 serotonin 1A agonist Substances 0.000 description 1
239000002485 serotonin 2C agonist Substances 0.000 description 1
239000000198 serotonin 5-HT3 receptor agonist Substances 0.000 description 1
239000003762 serotonin receptor affecting agent Substances 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
230000002295 serotoninergic effect Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
239000000779 smoke Substances 0.000 description 1
229940124535 smoking cessation aid Drugs 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
229960000912 stanozolol Drugs 0.000 description 1
208000005809 status epilepticus Diseases 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
230000035882 stress Effects 0.000 description 1
230000002739 subcortical effect Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
230000003977 synaptic function Effects 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229950007352 talopram Drugs 0.000 description 1
LJBBMCNHIUJBDU-UHFFFAOYSA-N talopram Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 LJBBMCNHIUJBDU-UHFFFAOYSA-N 0.000 description 1
BRPOADLGOFPKKJ-UHFFFAOYSA-N tandamine Chemical compound C12=CC=CC=C2N(CC)C2=C1CCSC2(C)CCN(C)C BRPOADLGOFPKKJ-UHFFFAOYSA-N 0.000 description 1
229950006964 tandamine Drugs 0.000 description 1
CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
229950000505 tandospirone Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229960003188 temazepam Drugs 0.000 description 1
201000008914 temporal lobe epilepsy Diseases 0.000 description 1
FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 description 1
229930003945 thebaine Natural products 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
230000008719 thickening Effects 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
208000004371 toothache Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000583 toxicological profile Toxicity 0.000 description 1
229940100640 transdermal system Drugs 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229960003741 tranylcypromine Drugs 0.000 description 1
MEHHPFQKXOUFFV-OWSLCNJRSA-N trenbolone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@H](CC3)O)C=C3)C3=C21 MEHHPFQKXOUFFV-OWSLCNJRSA-N 0.000 description 1
229960000312 trenbolone Drugs 0.000 description 1
JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
229960003386 triazolam Drugs 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229960002431 trimipramine Drugs 0.000 description 1
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
229960001641 troglitazone Drugs 0.000 description 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
229950010342 uridine triphosphate Drugs 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
HDVXJTYHXDVWQO-UHFFFAOYSA-N valeranone Natural products C1CCC(=O)C2(C)CC(C(C)C)CCC21C HDVXJTYHXDVWQO-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005172 vertebrate brain Anatomy 0.000 description 1
NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
229940002552 xenical Drugs 0.000 description 1
HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
229960004010 zaleplon Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229960000820 zopiclone Drugs 0.000 description 1
AXORVIZLPOGIRG-UHFFFAOYSA-N β-methylphenethylamine Chemical compound NCC(C)C1=CC=CC=C1 AXORVIZLPOGIRG-UHFFFAOYSA-N 0.000 description 1

JP2017555768A 2015-04-27 2016-04-26 ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法 Active JP6675688B2 (ja)